Insilico Medicine, a developer specializing in generative AI for drug discovery, announced on Sunday a global licensing and research agreement with U.S. pharmaceutical giant Eli Lilly. The deal, potentially valued at up to $2.75 billion including milestone payments, marks a significant advancement in AI-driven drug development.
Pharmaceutical companies are increasingly adopting artificial intelligence to speed up research and development processes. This trend aligns with efforts by the U.S. Food and Drug Administration to minimize animal testing, as AI-powered modeling and automated laboratories promise greater efficiency across drug pipelines.
Under the terms of the agreement, Eli Lilly will obtain an exclusive license to develop, manufacture, and commercialize preclinical oral drug candidates created by Insilico Medicine, targeting specific disease areas. The Hong Kong-listed firm disclosed this in a regulatory filing.
Insilico Medicine will receive an upfront payment of $115 million and stands to earn additional development, regulatory, and commercial milestone payments that could raise the total deal value to approximately $2.75 billion. The company will also benefit from tiered royalties on future sales.
In a notable development, Eli Lilly will acquire exclusive rights to market a GLP-1 drug for diabetes developed by Insilico Medicine, highlighting the strategic importance of this collaboration in the diabetes treatment market.
